Loading…
DVA
Davita Inc
NYSE· Healthcare· Medical Care Facilities
$180.68+1.01%
Key metrics
- Market cap
- $11.53B
- P/E
- 15.2x
- Forward P/E
- 10.5x
- P/B
- —
- Dividend yield
- —
- EPS
- $11.92
- ROE
- 88.47%
- Profit margin
- 6.05%
- Revenue growth
- +5.20%
- Beta
- 0.87
- 52-week high
- $247.49
- 52-week low
- $101.00
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- 78,000
- Denver, United States
Company description provided by Yahoo Finance.
